$2.06
1.90%
Nasdaq, Sep 25, 04:00 pm EDT. Closed.
ISIN
US45719W1062
Symbol
IKT

Inhibikase Therapeutics Inc Stock price

$2.06
-0.44 17.60% 1M
+0.43 26.38% 6M
+0.01 0.49% YTD
+0.51 32.90% 1Y
+0.79 62.20% 3Y
-9.82 82.66% 5Y
-57.34 96.53% 10Y
-57.34 96.53% 20Y
Nasdaq, Closing price Fri, Sep 25 2026
-0.04 1.90%
ISIN
US45719W1062
Symbol
IKT
Industry

Is Inhibikase Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$287.4m
Enterprise Value
$128.4m
Net debt
positive
Cash
$159.0m
Shares outstanding
132.0m
Valuation (TTM | estimate)
P/E
-
P/S
- | 853.8
EV/Sales
- | 381.4
EV/FCF
negative
P/B
1.9
Financial Health
Equity Ratio
95.4%
Return on Equity
-
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $336.7k
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
$-42.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-109.3%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
-
FCF per Share
$-0.3
Short interest
20.7%
Employees
35
Rev per Employee
-

Inhibikase Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Inhibikase Therapeutics Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Inhibikase Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Inhibikase Therapeutics Inc

Dec '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 24 24
107% 107%
-
- Research and Development Expense 22 22
30% 30%
-
-45 -45
56% 56%
-
- Depreciation and Amortization 0.06 0.06
100% 100%
-
EBIT (Operating Income) EBIT -45 -45
56% 56%
-
Net Profit -48 -48
75% 75%
-

In millions USD.

Don't miss a Thing! We will send you all news about Inhibikase Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inhibikase Therapeutics Inc Stock News

Neutral
GlobeNewsWire
●
about 2 months ago
WILMINGTON, Del., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended June 30, 2026, and highlighted recent developments.
Neutral
GlobeNewsWire
●
2 months ago
WILMINGTON, Del., July 23, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to its lead product candidate IKT-001, a prodrug of imati...
Neutral
GlobeNewsWire
●
2 months ago
WILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today announced that it has sold 25,000,000 shares of the Company's common stock to RA Capital Management through its at-the-market (“ATM”) facility for gross proceeds ...
More Inhibikase Therapeutics Inc News

Company Profile

Inhibikase Therapeutics, Inc. provides infectious disease treatments. It develops small molecule platform for treating both bacterial and viral infectious diseases. It operates through RAMP™ Drug Innovation Engine technology. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.

Head office United States
CEO Mr. Iwicki
Employees 35
Founded 2008
Website www.inhibikase.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today